Bausch Health Companies Inc. (BHC)
Automate Your Wheel Strategy on BHC
With Tiblio's Option Bot, you can configure your own wheel strategy including BHC - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol BHC
- Rev/Share 27.8221
- Book/Share 1.0175
- PB -3.9996
- Debt/Equity -38.2804
- CurrentRatio 1.473
- ROIC 0.0296
- MktCap 2215691217.0
- FreeCF/Share 2.6814
- PFCF 2.2301
- PE 14.2697
- Debt/Assets 0.8043
- DivYield 0
- ROE -0.2026
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 3
- DCF Score 4
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | BHC | Barclays | -- | Equal Weight | -- | $8 | Dec. 9, 2025 |
News
Bausch Health's Aesthetics Business, Solta Medical, Announces the Launch of Clear + Brilliant® Touch Laser in Canada
Published: February 23, 2026 by: PRNewsWire
Sentiment: Neutral
LAVAL, QC, Feb. 23, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), a global, diversified pharmaceutical company, and Solta Medical, a global leader in medical aesthetics, today announced the launch of the Clear + Brilliant® Touch laser in Canada. The device was approved by Health Canada on May 20, 2025, marking an important milestone as demand for non‑invasive skin rejuvenation treatments continues to grow across Canada.
Read More
Ironwood vs. Bausch Health: Which GI Drug Stock is a Better Pick Now?
Published: February 20, 2026 by: Zacks Investment Research
Sentiment: Neutral
IRWD has the edge over BHC with high Linzess demand and upbeat 2026 revenue outlook offsetting pipeline and pricing risks.
Read More
Bausch + Lomb Q4 Earnings Review: Still A Buy, With Some Caveats
Published: February 19, 2026 by: Seeking Alpha
Sentiment: Positive
Bausch + Lomb delivered 7% constant currency Q4 revenue growth and 27% adjusted EBITDA growth, reinforcing strong operating leverage. I maintain my Buy rating on BLCO, citing robust revenue momentum, promising product pipelines, and a path toward improved profitability and valuation. BLCO targets 5–7% annual revenue growth through 2028, driven by innovation in contact lenses, dry eye therapies, and premium intraocular lenses.
Read More
BHC Stock Down on Q4 Earnings Miss, Salix Drives Revenue Growth
Published: February 19, 2026 by: Zacks Investment Research
Sentiment: Neutral
Bausch stock slips as Q4 EPS misses despite 9% revenue growth, strong Salix and Bausch + Lomb gains, and an upbeat 2026 sales outlook.
Read More
How Bausch Health's Turnaround Progressed In Q4 2025
Published: February 19, 2026 by: Seeking Alpha
Sentiment: Positive
How Bausch Health's Turnaround Progressed In Q4 2025
Read More
Curious about Bausch (BHC) Q4 Performance? Explore Wall Street Estimates for Key Metrics
Published: February 17, 2026 by: Zacks Investment Research
Sentiment: Neutral
Get a deeper insight into the potential performance of Bausch (BHC) for the quarter ended December 2025 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.
Read More
What to Expect From These Drug/Biotech Players This Earnings Season?
Published: February 16, 2026 by: Zacks Investment Research
Sentiment: Neutral
Let's take a closer look at what awaits Bausch Health, Amicus Therapeutics, BioMarin Pharmaceutical, Insmed and Madrigal Pharmaceuticals as they prepare to report quarterly results this week.
Read More
Bausch Health (BHC) Reports Next Week: Wall Street Expects Earnings Growth
Published: February 11, 2026 by: Zacks Investment Research
Sentiment: Positive
Bausch (BHC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
BHC's Late-Stage Liver Cirrhosis Studies Fail, Stock Down
Published: January 27, 2026 by: Zacks Investment Research
Sentiment: Negative
Bausch Health shares slide after late-stage RED-C trials for rifaximin SSD fail, derailing plans to expand Xifaxan's cirrhosis-related use.
Read More
Down 17.9% in 4 Weeks, Here's Why You Should You Buy the Dip in Bausch (BHC)
Published: January 26, 2026 by: Zacks Investment Research
Sentiment: Positive
Bausch (BHC) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Read More
2 Strong Mid-Cap Growth Stocks Dan Loeb Bought in Q3
Published: December 29, 2025 by: 24/7 Wall Street
Sentiment: Positive
Dan Loeb of Third Point is a brilliant investor worth watching closely whenever the 13F filings roll in.
Read More
Bausch Health Announces Final Results and Expiration of Exchange Offers
Published: December 23, 2025 by: Accesswire
Sentiment: Neutral
LAVAL, QC / ACCESS Newswire / December 23, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) (the "Company") and its subsidiary 1261229 B.C. Ltd. (the "Issuer" and, together with the Company, the "Offerors") today announced the final results and expiration of their previously announced offers to exchange the Company's outstanding 4.875% Senior Secured Notes due 2028 (the "4.875% Notes") and 11.00% Senior Secured Notes due 2028 (the "11.00% Notes" and together with the 4.875% Notes, the "Existing Senior Secured Notes") for up to $1.6 billion aggregate principal amount of the Issuer's 10.00% Senior Secured Notes due 2032 (the "New Notes" and, …
Read More
BHC Stock Up as Solta Acquires Shibo's Aesthetics Distribution Business
Published: December 02, 2025 by: Zacks Investment Research
Sentiment: Positive
BHC jumps 11% as Solta Medical acquires Wuhan Shibo Zhenmei, gaining full control of its China aesthetics distribution business.
Read More
Bausch Health Companies Inc. (BHC) Presents at Evercore 8th Annual Healthcare Conference Transcript
Published: December 02, 2025 by: Seeking Alpha
Sentiment: Neutral
Bausch Health Companies Inc. (BHC) Presents at Evercore 8th Annual Healthcare Conference Transcript
Read More
Bausch (BHC) Upgraded to Buy: Here's Why
Published: November 19, 2025 by: Zacks Investment Research
Sentiment: Positive
Bausch (BHC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Read More
Bausch Health to Participate in the 8th Annual Evercore Healthcare Conference
Published: November 18, 2025 by: Accesswire
Sentiment: Neutral
LAVAL, QC / ACCESS Newswire / November 18, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), today announced that Jean-Jacques Charhon, Executive Vice President and Chief Financial Officer, will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference in Coral Gables, Florida on December 2, 2025. A live audio webcast of the event will be accessible on the Investor Relations section of Bausch Health's website.
Read More
Will Bausch (BHC) Gain on Rising Earnings Estimates?
Published: November 10, 2025 by: Zacks Investment Research
Sentiment: Positive
Bausch Health (BHC) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Read More
BHC Stock Up on Q3 Earnings Beat, Salix and Solta Drive Sales
Published: October 30, 2025 by: Zacks Investment Research
Sentiment: Positive
Bausch Health's Q3 results top expectations as strong Salix and Solta sales fuel growth. Shares gain.
Read More
Bausch Health (BHC) Expected to Beat Earnings Estimates: Should You Buy?
Published: October 22, 2025 by: Zacks Investment Research
Sentiment: Positive
Bausch (BHC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
Activist Investor Seeks Strategic Overhaul At Contact Lens Maker Cooper, Suggests Merger With Bausch + Lomb
Published: October 20, 2025 by: Benzinga
Sentiment: Positive
Activist investor Jana Partners has reportedly taken a stake in The Cooper Companies (NASDAQ:COO) and is pressing the medical-device maker to evaluate strategic alternatives — including a potential merger between its contact-lens division and Bausch + Lomb (NYSE:BLCO).
Read More
Bausch Health's Aesthetic Business, Solta Medical, Brings Non-Invasive Aesthetic Innovations to National TV
Published: September 30, 2025 by: Accesswire
Sentiment: Neutral
The Balancing Act airing on Lifetime will showcase how innovative treatments Thermage® FLX, Clear + Brilliant®, and Fraxel FTX™ offer energy-based treatment options that help maintain a youthful appearance while enhancing natural beauty. LAVAL, QC / ACCESS Newswire / September 30, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), a global, diversified pharmaceutical company, and its aesthetic business, Solta Medical, a global leader in the medical aesthetics market, will be featured on The Balancing Act, airing on Lifetime, in a special episode spotlighting its portfolio of non-invasive skin rejuvenation and tightening technologies: Thermage® FLX, Clear + Brilliant® and Fraxel FTX™.
Read More
Bausch Health to Announce Third Quarter 2025 Results on October 29
Published: September 30, 2025 by: Accesswire
Sentiment: Neutral
LAVAL, QC / ACCESS Newswire / September 30, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) will release third quarter 2025 financial results after market close on Wednesday, October 29, 2025. Bausch Health will host a live conference call and webcast at 5:00 p.m.
Read More
Bausch Health: Repricing Continues As Deleveraging Gains Traction
Published: September 11, 2025 by: Seeking Alpha
Sentiment: Positive
Bausch Health remains a Buy as the market overstates debt and patent risks, while the business shows stable cash generation and operational momentum. Q2 results confirmed growth in core segments, improved profitability, and management's commitment to debt reduction and strategic portfolio development. Despite a heavy debt load, refinancing progress and upgraded 2025 guidance support my thesis of undervaluation and a 27% upside to $9.1 per share.
Read More
Bausch (BHC) Up 21.4% Since Last Earnings Report: Can It Continue?
Published: August 29, 2025 by: Zacks Investment Research
Sentiment: Positive
Bausch (BHC) reported earnings 30 days ago. What's next for the stock?
Read More
Bausch Health Announces Increase in Shareholding by its Chairperson of the Board and Board Changes
Published: August 15, 2025 by: Accesswire
Sentiment: Neutral
LAVAL, QC / ACCESS Newswire / August 15, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) ("Bausch Health" or the "Company") today announced that Paulson Capital Inc. and certain affiliates and managed funds have increased their ownership of the Company's common shares. The increase reflects the acquisition by Paulson Capital Inc. and certain affiliates and managed funds of the net long position of 34,721,118 common shares previously held by Mr.
Read More
Why Bausch Health Stock Surged By Nearly 20%
Published: August 12, 2025 by: Seeking Alpha
Sentiment: Positive
Bausch Health surged by nearly 20% on high volume on Monday, rebounding from a post-earnings sell-off driven by high risk and debt concerns. Q2 results beat revenue and GAAP EPS estimates, with strong growth in Xifaxan and Solta Medical, but normalized EPS missed slightly. Debt reduction remains slow, with only $11 million paid down against $14.65 billion net debt.
Read More
Bausch Health Stock Falls on Q2 Earnings Miss, Revenues Beat
Published: July 31, 2025 by: Zacks Investment Research
Sentiment: Negative
BHC stock falls 6.3% as Q2 earnings miss estimates despite stronger sales and growth in key segments like Salix and Solta Medical.
Read More
Bausch Health Adds Late-Stage Ready Alcohol Liver Disease Drug Candidate In $63 Million DURECT Buyout
Published: July 29, 2025 by: Benzinga
Sentiment: Positive
Bausch Health Companies Inc. BHC on Tuesday agreed to indirectly acquire DURECT Corp DRRX, including a novel therapeutic molecule, larsucosterol.
Read More
Bausch Health to Reduce Debt by Approximately $900 Million Using Cash On Hand
Published: July 28, 2025 by: Accesswire
Sentiment: Neutral
LAVAL, QC / ACCESS Newswire / July 28, 2025 / Bausch Health Companies Inc. (NYSE: BHC)(TSX: BHC) ("Bausch Health" or the "Company") today announced that its subsidiary, Bausch Health Americas, Inc., has issued an irrevocable notice of redemption pursuant to which it will redeem approximately $602 million of aggregate principal amount of its outstanding 9.25% Senior Notes due 2026, CUSIP Nos. 91911XAV6 and U9098VAN2 (the "Notes"), using cash on hand.
Read More
Five Popular Stocks Insiders Have Been Aggressively Buying
Published: June 24, 2025 by: 24/7 Wall Street
Sentiment: Positive
We have to consider that insiders buying their stock wouldn't put up their own money unless they believed the move would be profitable.
Read More
About Bausch Health Companies Inc. (BHC)
- IPO Date 1994-03-29
- Website https://www.bauschhealth.com
- Industry Drug Manufacturers - Specialty & Generic
- CEO Thomas J. Appio
- Employees 20700